Key Takeaways Regeneron posted Q3 EPS of $11.83, topping estimates but down 5$3.7B, driven by Dupixent's 27% surge and Eylea HD's growing demand.Libtayo sales climbed 27%, while new oncology approvals strengthen Regeneron's therapeutic portfolio.Regeneron Pharmaceuticals, Inc. (REGN) reported third-quarter 2025 adjusted earnings per share (EPS) of $11.83, which comfortably beat the Zacks Consensus Estimate of$9.44. However, the bottom line was down 5% fr ...